This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Lennox-Gastaut syndromeLennox-Gastaut Syndrome (LGS)

Contents — quick navigation
ABasic informationICD-10: G40.4 | Special Copayment Reduction: V233 | Coverage period: 5 years
BSynonymsLennox syndrome, myoclonic-atonic epilepsy (distinguished by some)
CAdult onsetLikelihood of first onset in adulthood low — onset at 1~8 years, persists into adulthood, but new onset occurs in childhood
S1HistoryThe process of establishing the concept of epileptic encephalopathy that began with the work of Lennox and Gastaut
S2CausesCause identifiable in 65~80%, including structural, metabolic, genetic, and unknown
S3GeneticsMany genes involved, including CDKL5, SCN1A, SCN2A, KCNQ2, ARX
S4General epidemiologyPrevalence 0.1~0.28/1,000; 1~4% of all childhood epilepsy
S5PathophysiologyCortico-thalamic network abnormality, widespread seizure propagation due to inhibitory–excitatory imbalance
S6SymptomsMultiple seizure types (tonic, atonic, atypical absence), cognitive decline, behavioral abnormalities
S7SignsSlow spike-wave complexes (<2.5 Hz) on EEG, fast rhythms during sleep, drop attacks
S8ScreeningEEG, neurodevelopmental assessment, metabolic screening
S9DiagnosisClinical diagnosis based on the triad (seizures, EEG, cognition), MRI, gene panel
S10TreatmentPolytherapy with valproate, clobazam, rufinamide, cannabidiol, etc.
S11PrognosisMostly treatment-refractory; seizures persist into adulthood, cognitive impairment accumulates
S12PreventionFundamental prevention difficult; early diagnosis and treatment of the cause can improve the course
S13References10 key references

S1. History

The clinical description of Lennox-Gastaut syndrome (LGS) began in the 1930s~1940s with William Gordon Lennox and his colleague Margaret Lennox. In 1945, Lennox used the term "petit mal variant" while describing a particular seizure pattern associated with toxic encephalopathy. Later, in 1966, the French neurologist Henri Gastaut systematically organized the electroclinical features of this syndrome and presented slow spike-wave (SSW) complexes as the key EEG finding. Gastaut clearly distinguished the characteristic seizure triad of tonic seizures, atonic seizures, and atypical absence seizures, and emphasized that cognitive impairment is an essential element of the syndrome. In honor of this work, the International League Against Epilepsy (ILAE) named the syndrome after both researchers.

In the 1960s~1970s, along with advances in EEG technology, attempts were made to understand LGS as an evolved form of infantile spasms (West syndrome). In fact, about 20~30% of patients with infantile spasms are known to later transition to LGS. In the 1981 ILAE seizure classification and the 1989 classification of epilepsies and epileptic syndromes, LGS was formally classified as an independent developmental epileptic encephalopathy (DEE).

Since the 2000s, with the introduction of next-generation genomic analysis (NGS, whole exome sequencing), the genetic causes of LGS have begun to be identified to a considerable extent. In addition, surgical and non-pharmacological treatments such as the ketogenic diet, vagus nerve stimulation (VNS), and corpus callosotomy were introduced into clinical practice. In 2018, cannabidiol (CBD) received US FDA approval, expanding the pharmacological treatment options for LGS, and in the 2020s clinical studies of deep brain stimulation (DBS) are also under way.

S2. Causes

LGS is a heterogeneous syndrome arising from diverse causes. By cause, it is classified as structural, metabolic, genetic, or of unknown cause (idiopathic). The cause is identified in about 65~80% of all patients.

Structural causes

Metabolic causes

Hereditary causes

Unknown cause

In about 20~35%, the cause cannot be identified with current diagnostic technology. In this case, it is classified as idiopathic LGS or LGS of unclear cause.

S3. Genetics

LGS is not a disease of a single genetic cause but an electroclinical syndrome arising from diverse genetic and acquired causes. With advances in genomic analysis technology, numerous gene variants are being identified in patients with LGS.

Major associated genes

GeneProtein/functionPathogenic mechanism
SCN1ANav1.1 sodium channelReduced inhibitory interneuron function (overlaps with Dravet syndrome)
SCN2ANav1.2 sodium channelDisruption of excitatory/inhibitory balance
KCNQ2Kv7.2 potassium channelImpaired neuronal repolarization
CDKL5CDKL5 protein kinaseAbnormal synapse formation and dendrite development
STXBP1Regulation of neurotransmitter releaseSynaptic dysfunction
ARXTranscription factorAbnormal GABAergic interneuron development
TSC1/TSC2Hamartin/tuberinmTOR hyperactivation, cortical tuber formation

Next-generation genomic analysis (whole exome/genome sequencing) shows a diagnostic yield of about 30~50% in patients with LGS. De novo mutations are particularly important and are the main mechanism by which a genetic cause is found in patients without a family history. Tuberous sclerosis complex (TSC) is one of the most common single genetic causes of LGS, with LGS developing in about 30~40% of TSC patients.

Genotype–phenotype correlations are established for some genes, but incomplete penetrance and variable expressivity are observed, with diverse phenotypes appearing even with the same gene variant. Gene panel testing or whole-exome testing is recommended after the diagnosis of LGS to identify the cause and for recurrence counseling.

S4. General epidemiology

LGS is a rare epilepsy syndrome occurring worldwide, with an estimated prevalence of about 0.1~0.28 per 1,000 population. It accounts for 1~4% of all childhood epilepsy and is observed at higher proportions in treatment-refractory epilepsy clinics.

The age of onset is typically 1~8 years, with a peak at 3~5 years. It tends to be slightly more common in boys, but the sex difference is not marked. No differences in prevalence by ethnicity have been reported, but differences in access to diagnosis due to socioeconomic factors may affect prevalence estimates.

The rate of transition from West syndrome (infantile spasms) to LGS is known to be about 20~30%. In addition, the incidence is high in patients with preceding conditions such as focal cortical dysplasia, tuberous sclerosis, and hypoxic-ischemic encephalopathy.

In Korea, epidemiological studies based on Health Insurance Review & Assessment Service (HIRA) data include LGS as a major cause of pediatric epileptic encephalopathy, and the number of patients registered for Special Copayment Reduction (V233) is increasing every year. Adult patients are mostly patients whose disease began in childhood and has continued into adulthood; new onset in adults is extremely rare.

S5. Pathophysiology

The pathophysiology of LGS has not been fully elucidated, but abnormal synchronization of the cortico-thalamic network has been proposed as the key mechanism. The normal cortico-thalamic circuit is essential for sleep–wake cycles and cognitive processing, and in LGS excessive synchronization of this circuit causes widespread seizure propagation.

Inhibitory–excitatory imbalance

Reduced function of GABAergic inhibitory interneurons and a relative increase in glutamatergic excitation are observed. In particular, damage to inhibitory networks in the frontal lobe and throughout the cortex is thought to cause multiple seizure types.

Mechanism of slow spike-wave complex formation

Slow spike–slow wave complexes (1.5~2.5 Hz) originate from abnormal oscillation of the cortico-thalamic loop. The alternating inhibitory–excitatory cycle between the reticular nucleus of the thalamus and the cortex is impaired, producing synchronized low-frequency discharges. This is a pathophysiological feature that distinguishes them from the 3 Hz spike-wave of classic absence seizures.

Fast rhythms during sleep

Fast polyspikes occurring during sleep (generalized paroxysmal fast activity, GPFA; ≥10 Hz) are closely associated with tonic seizures. GPFA reflects a hyperexcitable state of the brainstem–cortical pathway and is observed just before the onset of tonic seizures. These sleep EEG findings are an important supportive criterion for the diagnosis of LGS.

Structural brain basis

Malformations of cortical development, white matter injury, cortical atrophy, and other findings identified on MRI are observed in LGS of structural cause, and these structural abnormalities form the basis for abnormal network formation. In tuberous sclerosis, cortical tubers act as seizure onset sites.

S6. Symptoms

The core clinical features of LGS are the triad of multiple seizure types, cognitive impairment, and behavioral abnormalities.

Seizure types

Seizure typesClinical featuresFrequency
Tonic seizureSudden muscle tension, generalized stiffening, lasting seconds to tens of seconds; frequent during sleepMost common
Atonic seizureFalls (drop attacks) due to sudden loss of muscle tone; risk of serious injuryCommon
Atypical absence seizureGradual onset and offset; consciousness partially preserved; tens of seconds to several minutesCommon
Myoclonic seizureBrief muscle contractions; present in some patientsLess common
Tonic-clonic seizureSecondary generalization possibleSome

Cognitive and behavioral abnormalities

Intellectual disability is an essential element of LGS but may not be evident early in the disease. Cognitive function gradually declines over time. Attention deficit, hyperactivity, autism spectrum features, and aggressive behavior may accompany it. Delayed language development and communication disorders are common.

Other clinical features

Repeated falls due to atonic and tonic seizures cause physical complications such as head trauma, dental injuries, and fractures. The incidence of status epilepticus is high, and nonconvulsive status epilepticus in particular can be a cause of impaired consciousness.

S7. Signs

The clinical signs of LGS are divided into EEG findings and neurological examination findings.

EEG findings

Neurological signs

On neurological examination, muscle tone abnormalities (hypotonia or hypertonia), cerebellar signs, pyramidal tract signs, and others are observed variably depending on the underlying disease. Because of repeated falls causing head trauma, there may be evidence of skull fractures, scalp scars, etc. When tuberous sclerosis is the cause, skin findings (ash-leaf spot, shagreen patch, adenoma sebaceum) are observed.

S8. Screening

Screening and initial evaluation of LGS proceed in the following steps.

EEG testing

Prolonged video-EEG monitoring including wake and sleep EEG is essential. Confirmation of slow spike–slow wave complexes (1.5~2.5 Hz) and GPFA during sleep is the key to diagnosis. Characteristic findings can be confirmed with interictal EEG alone, but ictal EEG is essential for classifying seizure types.

Neurodevelopmental assessment

A comprehensive neuropsychological assessment is needed, including intelligence quotient (IQ) testing, language development assessment, adaptive behavior assessment, and autism spectrum screening tools (M-CHAT, ADOS, etc.).

Metabolic screening

Analysis of blood and urine metabolites (amino acids, organic acids, ammonia, lactate, etc.) and screening for inborn errors of metabolism are needed to identify the cause. Cerebrospinal fluid testing (glucose, protein, neurotransmitters) is also considered.

S9. Diagnosis

The diagnosis of LGS is a clinical diagnosis based on the clinical triad (multiple seizure types, characteristic EEG, cognitive impairment).

Diagnostic criteria (ILAE)

Imaging

Evaluation of structural causes by brain MRI (3T preferred). Malformations of cortical development, corpus callosum abnormalities, tuberous sclerosis lesions, hypoxic-ischemic injury, etc. are identified. PET, fMRI, and MEG are additionally performed when evaluating for surgical treatment.

Genetic testing

When the cause is unknown or a genetic cause is suspected, an epilepsy gene panel or whole exome/genome analysis is performed. Simultaneous testing of the parents (trio analysis) is efficient for identifying de novo mutations.

Differential diagnosis

DiseaseDistinguishing points
Dravet syndromeSCN1A mutation, febrile seizures, predominance of myoclonic seizures
West syndromeInfantile spasms, hypsarrhythmia, onset within the first 12 months of life
Absence epilepsy3 Hz spike-wave, normal cognition, good treatment response
CSWS (continuous spike-waves during slow-wave sleep)Continuous spike-wave during sleep, cognitive regression

S10. Treatment

LGS is highly treatment-refractory, so most patients require polytherapy.

First-line antiseizure medications

Second-line and add-on drugs

Non-pharmacological treatment

S11. Prognosis

LGS mostly shows a treatment-refractory course, and severe neurological damage accumulates over the long term.

About 80% of LGS patients who survive into adulthood are unable to carry out daily living independently and require ongoing medical and social support.

S12. Prevention

Fundamental prevention of LGS itself is currently impossible. However, the risk of onset can be partly reduced through early diagnosis and treatment of underlying diseases, perinatal management, and the like.

In patients diagnosed with LGS, prevention of secondary complications is important, including seizure monitoring to reduce SUDEP risk (nocturnal seizure detectors, etc.), wearing protective equipment to prevent injuries from falls, and restricting hazardous activities such as swimming and climbing.

S13. References

  1. Arzimanoglou A, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93. PMID: 19081517.
  2. Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376:2011-2020. PMID: 28538134.
  3. Thiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096. PMID: 29764202.
  4. Gastaut H, et al. The Lennox-Gastaut syndrome: clinical and electroencephalographic study of 60 cases. Epilepsia. 1966;7(4):361-384.
  5. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6):1001-1019. PMID: 19337453.
  6. Kossoff EH, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175-192. PMID: 29881797.
  7. Montouris G, et al. Lennox-Gastaut syndrome in adults. Epileptic Disord. 2014;16(S1):S26-S38. doi:10.1684/epd.2014.0651.
  8. Specchio N, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood. Epilepsia. 2022;63(6):1398-1442. PMID: 35503717.
  9. Cross JH, et al. The epileptic encephalopathies. In: Handbook of Clinical Neurology. 2013;111:619-626. doi:10.1016/B978-0-444-52891-9.00064-6.
  10. Goldsmith IL, et al. Corpus callosotomy for medically intractable seizures in pediatric patients. Epilepsia. 2000;41(12):1585-1592. PMID: 11114222.